Fatty liver disease

Short description: Medical condition where fat accumulates in the liver

Fatty liver

Other names| Hepatic steatosis
Micrograph showing a fatty liver (macrovesicular steatosis), as seen in metabolic dysfunction–associated steatotic liver disease. Trichrome stain.
Specialty| Gastroenterology
Symptoms| None, tiredness, pain in the upper right side of the abdomen[1][2]
Complications| Cirrhosis, liver cancer, esophageal varices[1][3]
Types| Metabolic dysfunction–associated steatotic liver disease (MASLD), alcoholic liver disease (ALD)[1]
Causes| Alcohol, diabetes, obesity[3][1]
Diagnostic method| Based on the medical history supported by blood tests, medical imaging, liver biopsy[1]
Differential diagnosis| Viral hepatitis, Wilson's disease, primary sclerosing cholangitis[3]
Treatment| Avoiding alcohol, weight loss[3][1]
Prognosis| Good if treated early[3]
Frequency| NAFLD: 30% (Western countries)[2]
ALD: >90% of heavy drinkers[4]

Fatty liver disease (FLD), also known as hepatic steatosis and steatotic liver disease (SLD), is a condition where excess fat builds up in the liver.[1] Often there are no or few symptoms.[1][2] Occasionally there may be tiredness or pain in the upper right side of the abdomen.[1] Complications may include cirrhosis, liver cancer, and esophageal varices.[1][3]

The main subtypes of fatty liver disease are metabolic dysfunction–associated steatotic liver disease (MASLD) and alcoholic liver disease (ALD), with the category "metabolic and alcohol associated liver disease" (metALD) describing an overlap of the two.[5]

Until June 2023, MASLD and its more advanced form, metabolic dysfunction associated steatohepatits (MASH), were referred to as non-alcoholic fatty liver disease (NAFLD) and non-alcoholoc steatohepatitis (NASH), respectively.[6]. The change in terminology was decided in a modified Delphi process led by three large pan-national liver associations (the American Association for the Study of Liver Diseases, the European Association for the Study of the Liver and the Latin American Association for the Study of the Liver).[5]

The primary risks include alcohol, type 2 diabetes, and obesity.[1][3] Other risk factors include certain medications such as glucocorticoids, and hepatitis C.[1] It is unclear why some people with MASLD develop simple fatty liver and others develop metabolic dysfunction associated steatohepatitis (MASH), which is associated with poorer outcomes.[1] Diagnosis is based on the medical history supported by blood tests, medical imaging, and occasionally liver biopsy.[1]

Treatment of MASLD is generally by dietary changes and exercise to bring about weight loss.[1] In those who are severely affected, liver transplantation may be an option.[1] More than 90% of heavy drinkers develop fatty liver while about 25% develop the more severe alcoholic hepatitis.[4] MASLD affects about 30% of people in Western countries and 10% of people in Asia.[2] MASLD affects about 10% of children in the United States.[1] It occurs more often in older people and males.[3][7]

## Contents

* 1 Classification
* 2 Signs and symptoms
* 2.1 Complications
* 3 Causes
* 4 Pathology
* 5 Diagnosis
* 6 Treatment
* 7 Epidemiology
* 8 Research
* 9 In animals
* 10 References
* 11 External links

## Classification

Until 2023, fatty liver disease was classified into:

* Non-alcoholic fatty liver disease (NAFLD) made up of:[7][1]
* Non-alcoholic fatty liver (NAFL) or simple fatty liver
* Non-alcoholic steatohepatitis (NASH)
* Alcoholic liver disease (ALD).[1]

In 2023, a new nomenclature was chosen,[5][8] with the classifications including:

* Metabolic dysfunction–associated steatotic liver disease (MASLD), including:
* Metabolic dysfunction-associated steatohepatitis (MASH)
* Metabolic and alcohol associated liver disease (metALD). Describes those with MASLD who consume greater amounts of alcohol per week but not enough to be categorized as ALD)
* Alcohol-associated liver disease (ALD)
* Specific aetiology SLD (including drug-induced, monogenic diseases and others)

## Signs and symptoms

Often there are no or few symptoms.[1] Occasionally there may be tiredness or pain in the upper right side of the abdomen.[1]

### Complications

Fatty liver can develop into hepatic fibrosis, cirrhosis or liver cancer.[9] For people affected by MASLD, the 10-year survival rate was about 80%. The rate of progression of fibrosis is estimated to be one per 7 years in MASH and one per 14 years in MASLD, with an increasing speed.[10][11] There is a strong relationship between these pathologies and metabolic illnesses (diabetes type II, metabolic syndrome). These pathologies can also affect non-obese people, who are then at a higher risk.[9]

Less than 10% of people with cirrhotic alcoholic FLD will develop hepatocellular carcinoma,[12] the most common type of primary liver cancer in adults, but up to 45% people with MASH without cirrhosis can develop hepatocellular carcinoma.[13]

The condition is also associated with other diseases that influence fat metabolism.[14]

## Causes

Different stages of liver damage

Fatty liver (FL) is commonly associated with metabolic syndrome (diabetes, hypertension, obesity, and dyslipidemia), but can also be due to any one of many causes:[15][16]

Alcohol
Alcohol use disorder is one of the causes of fatty liver due to production of toxic metabolites like aldehydes during metabolism of alcohol in the liver. This phenomenon most commonly occurs with chronic alcohol use disorder.
Metabolic
abetalipoproteinemia, glycogen storage diseases, Weber–Christian disease, acute fatty liver of pregnancy, lipodystrophy
Nutritional
obesity, malnutrition, total parenteral nutrition, severe weight loss, refeeding syndrome, jejunoileal bypass, gastric bypass, jejunal diverticulosis with bacterial overgrowth
Drugs and toxins
amiodarone, methotrexate, diltiazem, expired tetracycline, highly active antiretroviral therapy, glucocorticoids, tamoxifen,[17] environmental hepatotoxins (e.g., phosphorus, mushroom poisoning)
Other
celiac disease,[18] inflammatory bowel disease, HIV, hepatitis C (especially genotype 3), and alpha 1-antitrypsin deficiency[19]

## Pathology

Micrograph of periportal hepatic steatosis, as may be seen due to steroid use, trichrome stain

The fatty change represents the intracytoplasmatic accumulation of triglycerides (neutral fats). At the beginning, the hepatocytes present small fat vacuoles (liposomes) around the nucleus (microvesicular fatty change). In this stage, liver cells are filled with multiple fat droplets that do not displace the centrally located nucleus. In the late stages, the size of the vacuoles increases, pushing the nucleus to the periphery of the cell, giving a characteristic signet ring appearance (macrovesicular fatty change). These vesicles are well-delineated and optically "empty" because fats dissolve during tissue processing. Large vacuoles may coalesce and produce fatty cysts, which are irreversible lesions. Macrovesicular steatosis is the most common form and is typically associated with alcohol, diabetes, obesity, and corticosteroids. Acute fatty liver of pregnancy and Reye's syndrome are examples of severe liver disease caused by microvesicular fatty change.[20] The diagnosis of steatosis is made when fat in the liver exceeds 5–10% by weight.[14][21][22]

Mechanism leading to hepatic steatosis

Defects in fatty acid metabolism are responsible for pathogenesis of FLD, which may be due to imbalance in energy consumption and its combustion, resulting in lipid storage, or can be a consequence of peripheral resistance to insulin, whereby the transport of fatty acids from adipose tissue to the liver is increased.[14][23] Impairment or inhibition of receptor molecules (PPAR-α, PPAR-γ and SREBP1) that control the enzymes responsible for the oxidation and synthesis of fatty acids appears to contribute to fat accumulation. In addition, alcohol use disorder is known to damage mitochondria and other cellular structures, further impairing cellular energy mechanism. On the other hand, non-alcoholic FLD may begin as excess of unmetabolised energy in liver cells. Hepatic steatosis is considered reversible and to some extent nonprogressive if the underlying cause is reduced or removed.[citation needed]

Micrograph of inflamed fatty liver (steatohepatitis)

Severe fatty liver is sometimes accompanied by inflammation, a situation referred to as steatohepatitis. Progression to alcoholic steatohepatitis (ASH) or metabolic dysfunction associated steatohepatitis (MASH) depends on the persistence or severity of the inciting cause. Pathological lesions in both conditions are similar. However, the extent of inflammatory response varies widely and does not always correlate with degree of fat accumulation. Steatosis (retention of lipid) and onset of steatohepatitis may represent successive stages in FLD progression.[24]

Liver disease with extensive inflammation and a high degree of steatosis often progresses to more severe forms of the disease.[25] Hepatocyte ballooning and necrosis of varying degrees are often present at this stage. Liver cell death and inflammatory responses lead to the activation of hepatic stellate cells, which play a pivotal role in hepatic fibrosis. The extent of fibrosis varies widely. Perisinusoidal fibrosis is most common, especially in adults, and predominates in zone 3 around the terminal hepatic veins.[26]

The progression to cirrhosis may be influenced by the amount of fat and degree of steatohepatitis and by a variety of other sensitizing factors. In alcoholic FLD, the transition to cirrhosis related to continued alcohol consumption is well-documented, but the process involved in non-alcoholic FLD is less clear.[citation needed]

## Diagnosis

Liver steatosis (fatty liver disease) as seen on CT Ultrasound showing diffuse increased echogenicity of the liver Flow chart for diagnosis[16]

| | | | Elevated liver enzyme| | |

|
|
|
|
|
|

| | | | | | | | | |
| | | Serology to exclude viral hepatitis| | |
| | | | | | | | | |
| | | Imaging study showing
fatty infiltrate| | |
| | | | | | | | | |
| | | Alcohol intake| | |
| | | | | | | | | | | |
| | | | |
| Less than two drinks per day‡| | More than two drinks per day‡| |
| | | | | | | | | | |
| Nonalcoholic fatty liver disease likely| | Alcoholic liver disease likely| |
‡ Criteria for nonalcoholic fatty liver disease:
consumption of ethanol less than 20 g/day for women and 30 g/day for men[27]

Most individuals are asymptomatic and are usually discovered incidentally because of abnormal liver function tests or hepatomegaly noted in unrelated medical conditions. Elevated liver enzymes are found in as many as 50% of patients with simple steatosis.[28]: 1794 The serum alanine transaminase (ALT) level usually is greater than the aspartate transaminase (AST) level in the nonalcoholic variant and the opposite in alcoholic FLD (AST:ALT more than 2:1). Simple blood tests may help to determine the magnitude of the disease by assessing the degree of liver fibrosis.[29] For example, AST-to-platelets ratio index (APRI score) and several other scores, calculated from the results of blood tests, can detect the degree of liver fibrosis and predict the future formation of liver cancer.[30]

Imaging studies are often obtained during the evaluation process. Ultrasonography reveals a "bright" liver with increased echogenicity. Pocket-sized ultrasound devices might be used as point-of-care screening tools to diagnose liver steatosis.[31] Medical imaging can aid in diagnosis of fatty liver; fatty livers have lower density than spleens on computed tomography (CT), and fat appears bright in T1-weighted magnetic resonance images (MRIs).

Histological diagnosis by liver biopsy is the most accurate measure of fibrosis and liver fat progression as of 2018.[9] Conventional imaging methods, such as ultrasound, CT and MRI, are not specific enough to detect fatty liver disease unless fat occupies at least 30% of the liver volume.[32]

More advanced imaging techniques are under investigation for both the diagnosis and monitoring of fatty liver disease patients, including elastography techniques (both ultrasound-based techniques and using magnetic resonance elastography) to measure the stiffness of the liver, which increases due to the accumulation of liver fibrosis.[33] Several studies have also explored the use of quantitative MRI techniques such as proton density fat-fraction mapping[34] and iron-corrected T1 (cT1) mapping techiques.[35]

## Treatment

Decreasing caloric intake by at least 30% or by approximately 750–1,000 kcal/day results in improvement in hepatic steatosis.[9] For people with MASLD or MASH, weight loss via a combination of diet and exercise was shown to improve or resolve the disease.[9] In more serious cases, medications that decrease insulin resistance, hyperlipidemia, and those that induce weight loss such as bariatric surgery as well as vitamin E have been shown to improve or resolve liver function.[9][16]

Bariatric surgery, while not recommended in 2017 as a treatment for FLD alone, has been shown to revert FLD, MASLD, MASH and advanced steatohepatitis in over 90% of people who have undergone this surgery for the treatment of obesity.[9][36]

In the case of long-term total-parenteral-nutrition-induced fatty liver disease, choline has been shown to alleviate symptoms.[37][38][39] This may be due to a deficiency in the methionine cycle.[40]

## Epidemiology

NAFLD affects about 30% of people in Western countries and 10% of people in Asia.[2] In the United States, rates are around 35% with about 7% having the severe form NASH.[1] NAFLD affects about 10% of children in the United States.[1] Recently the term Metabolic dysfunction-associated fatty liver disease (MAFLD) has been proposed to replace NAFLD. MAFLD is a more inclusionary diagnostic name as it is based on the detection of fatty liver by histology (biopsy), medical imaging or blood biomarkers but should be accompanied by either overweight/obesity, type 2 diabetes mellitus, or metabolic dysregulation.[41] The new definition no longer excludes alcohol consumption or coexistence of other liver diseases such as viral hepatitis. Using this more inclusive definition, the global prevalence of MAFLD is an astonishingly high 50.7%.[41] Indeed, also using the old NAFLD definition, the disease is observed in up to 80% of obese people, 35% of whom progress to NASH,[42] and in up to 20% of normal weight people,[11] despite no evidence of excessive alcohol consumption. FLD is the most common cause of abnormal liver function tests in the United States.[15] Fatty liver is more prevalent in Hispanic people than white, with black people having the lowest prevalence.[11]

In the study Children of the 90s, 2.5% born in 1991 and 1992 were found by ultrasound at the age of 18 to have non-alcoholic fatty liver disease; five years later transient elastography found over 20% to have the fatty deposits on the liver, indicating non-alcoholic fatty liver disease; half of those were classified as severe. The scans also found that 2.4% had a degree of liver fibrosis, which can lead to cirrhosis.[43][44]

After the lockdown of the COVID-19 pandemic, a study demonstrated that 48% of patients with liver steatosis gained weight, while 16% had a worsened steatosis grade. Weight gain was associated with poor adherence to the suggested diet, reduced levels of physical activity, and increased prevalence of homozygosity for the PNPLA3 rs738409 single nucleotide polymorphism.[45] PNPLA3 rs738409 is already a known risk factor for NAFLD.[46][47]

## Research

A systematic review and meta-analysis, published in 2024, found that growth hormone therapy may help in the management of fatty liver disease.[48]

## In animals

Fatty liver disease can occur in pets such as reptiles (particularly turtles[49]) and birds[50] as well as mammals like cats and dogs.[51] The most common cause is overnutrition. A distinct sign in birds is a misshapen beak. Fatty livers can be induced via gavage in geese or ducks to produce foie gras. Fatty liver can also be induced in ruminants such as sheep by a high-caloric diet.[52][53]

## References

1. ↑ 1.00 1.01 1.02 1.03 1.04 1.05 1.06 1.07 1.08 1.09 1.10 1.11 1.12 1.13 1.14 1.15 1.16 1.17 1.18 1.19 1.20 1.21 1.22 "Nonalcoholic Fatty Liver Disease & NASH". November 2016. https://www.niddk.nih.gov/health-information/liver-disease/nafld-nash/all-content.
2. ↑ 2.0 2.1 2.2 2.3 2.4 Singh, S; Osna, NA; Kharbanda, KK (28 September 2017). "Treatment options for alcoholic and non-alcoholic fatty liver disease: A review.". World Journal of Gastroenterology 23 (36): 6549–6570. doi:10.3748/wjg.v23.i36.6549. PMID 29085205.
3. ↑ 3.0 3.1 3.2 3.3 3.4 3.5 3.6 3.7 Antunes, Catiele; Azadfard, Mohammadreza; Hoilat, Gilles J.; Gupta, Mohit (2022). "Fatty Liver". StatPearls (StatPearls Publishing). PMID 28723021.
4. ↑ 4.0 4.1 Basra, Sarpreet (2011). "Definition, epidemiology and magnitude of alcoholic hepatitis". World Journal of Hepatology 3 (5): 108–113. doi:10.4254/wjh.v3.i5.108. PMID 21731902.
5. ↑ 5.0 5.1 5.2 Rinella, Mary E.; Lazarus, Jeffrey V.; Ratziu, Vlad; Francque, Sven M.; Sanyal, Arun J.; Kanwal, Fasiha; Romero, Diana; Abdelmalek, Manal F. et al. (2023). "A multi-society Delphi consensus statement on new fatty liver disease nomenclature" (in en-US). Hepatology 78 (6): 1966–1986. doi:10.1097/HEP.0000000000000520. ISSN 0270-9139. PMID 37363821.
6. ↑ DHANJAL, Adonia (24 June 2023). "Multinational liver societies announce new "Fatty" liver disease nomenclature that is affirmative and non-stigmatising". https://easl.eu/news/new_fatty_liver_disease_nomenclature-2/.
7. ↑ 7.0 7.1 Iser, D; Ryan, M (July 2013). "Fatty liver disease—a practical guide for GPs.". Australian Family Physician 42 (7): 444–7. PMID 23826593.
8. ↑ "A Liver Disease Gets a New Name, Diagnostic Criteria" (in en). http://www.medscape.com/viewarticle/994318.
9. ↑ 9.0 9.1 9.2 9.3 9.4 9.5 9.6 Chalasani, Naga; Younossi, Zobair; Lavine, Joel E.; Charlton, Michael; Cusi, Kenneth; Rinella, Mary; Harrison, Stephen A.; Brunt, Elizabeth M. et al. (January 2018). "The diagnosis and management of nonalcoholic fatty liver disease: Practice guidance from the American Association for the Study of Liver Diseases". Hepatology 67 (1): 328–357. doi:10.1002/hep.29367. PMID 28714183.
10. ↑ Singh, Siddharth; Allen, Alina M.; Wang, Zhen; Prokop, Larry J.; Murad, Mohammad H.; Loomba, Rohit (April 2015). "Fibrosis Progression in Nonalcoholic Fatty Liver vs Nonalcoholic Steatohepatitis: A Systematic Review and Meta-analysis of Paired-Biopsy Studies". Clinical Gastroenterology and Hepatology 13 (4): 643–654.e9. doi:10.1016/j.cgh.2014.04.014. PMID 24768810.
11. ↑ 11.0 11.1 11.2 Younossi, Zobair; Anstee, Quentin M.; Marietti, Milena; Hardy, Timothy; Henry, Linda; Eslam, Mohammed; George, Jacob; Bugianesi, Elisabetta (20 September 2017). "Global burden of NAFLD and NASH: trends, predictions, risk factors and prevention". Nature Reviews Gastroenterology & Hepatology 15 (1): 11–20. doi:10.1038/nrgastro.2017.109. PMID 28930295.
12. ↑ "Obesity, fatty liver and liver cancer". Hepatobiliary & Pancreatic Diseases International 4 (2): 173–7. May 2005. PMID 15908310.
13. ↑ Bellentani, Stefano (January 2017). "The epidemiology of non-alcoholic fatty liver disease". Liver International 37: 81–84. doi:10.1111/liv.13299. PMID 28052624.
14. ↑ 14.0 14.1 14.2 "Lipid metabolism and liver inflammation. II. Fatty liver disease and fatty acid oxidation". American Journal of Physiology. Gastrointestinal and Liver Physiology 290 (5): G852-8. May 2006. doi:10.1152/ajpgi.00521.2005. PMID 16603729.
15. ↑ 15.0 15.1 Angulo, Paul (18 April 2002). "Nonalcoholic Fatty Liver Disease". New England Journal of Medicine 346 (16): 1221–1231. doi:10.1056/NEJMra011775. PMID 11961152.
16. ↑ 16.0 16.1 16.2 "Nonalcoholic fatty liver disease". American Family Physician 73 (11): 1961–8. June 2006. PMID 16770927.
17. ↑ "Tamoxifen-induced non-alcoholic steatohepatitis: where are we now and where are we going?". Expert Opinion on Drug Safety 6 (1): 1–4. January 2007. doi:10.1517/14740338.6.1.1. PMID 17181445.
18. ↑ "Celiac disease-related hepatic injury: Insights into associated conditions and underlying pathomechanisms". Digestive and Liver Disease 48 (2): 112–9. February 2016. doi:10.1016/j.dld.2015.11.013. PMID 26711682.
19. ↑ "Alpha 1-antitrypsin mutations in NAFLD: high prevalence and association with altered iron metabolism but not with liver damage". Hepatology 44 (4): 857–64. October 2006. doi:10.1002/hep.21329. PMID 17006922.
20. ↑ Goldman, Lee (2003). Cecil Textbook of Medicine – 2-Volume Set, Text with Continually Updated Online Reference. Philadelphia: W.B. Saunders Company. ISBN 978-0-7216-4563-6.
21. ↑ "The natural history of nonalcoholic fatty liver disease: a population-based cohort study". Gastroenterology 129 (1): 113–21. July 2005. doi:10.1053/j.gastro.2005.04.014. PMID 16012941.
22. ↑ "Molecular mechanisms of alcoholic fatty liver: role of peroxisome proliferator-activated receptor alpha". Alcohol 34 (1): 35–8. August 2004. doi:10.1016/j.alcohol.2004.07.005. PMID 15670663.
23. ↑ "Approach to the pathogenesis and treatment of nonalcoholic steatohepatitis". Diabetes Care 27 (8): 2057–66. August 2004. doi:10.2337/diacare.27.8.2057. PMID 15277442.
24. ↑ "Steatohepatitis: a tale of two "hits"?". Gastroenterology 114 (4): 842–5. April 1998. doi:10.1016/S0016-5085(98)70599-2. PMID 9547102.
25. ↑ "Pathologic features associated with fibrosis in nonalcoholic fatty liver disease". Human Pathology 35 (2): 196–9. February 2004. doi:10.1016/j.humpath.2003.09.018. PMID 14991537.
26. ↑ "Non-alcoholic fatty liver disease: an emerging pathological spectrum". Virchows Archiv 444 (1): 3–12. January 2004. doi:10.1007/s00428-003-0943-7. PMID 14685853.
27. ↑ Adams, L. A.; Angulo, P; Lindor, KD (29 March 2005). "Nonalcoholic fatty liver disease". Canadian Medical Association Journal 172 (7): 899–905. doi:10.1503/cmaj.045232. PMID 15795412.
28. ↑ Reid, Andrea E. (2006). "Chapter 82: Nonalcoholic Fatty Liver Disease". in Feldman, Mark. Sleisenger and Fordtran's Gastrointestinal and Liver Disease (8th ed.). Philadelphia: W.B. Saunders Company. ISBN 978-1-4160-0245-1. https://archive.org/details/sleisengerfordtr0000unse_j1o5. Retrieved 4 July 2023.
29. ↑ Peleg, Noam; Issachar, Assaf; Sneh-Arbib, Orly; Shlomai, Amir (October 2017). "AST to Platelet Ratio Index and fibrosis 4 calculator scores for non-invasive assessment of hepatic fibrosis in patients with non-alcoholic fatty liver disease". Digestive and Liver Disease 49 (10): 1133–1138. doi:10.1016/j.dld.2017.05.002. PMID 28572039.
30. ↑ Peleg, Noam; Sneh Arbib, Orly; Issachar, Assaf; Cohen-Naftaly, Michal; Braun, Marius; Shlomai, Amir (14 August 2018). "Noninvasive scoring systems predict hepatic and extra-hepatic cancers in patients with nonalcoholic fatty liver disease". PLOS ONE 13 (8). doi:10.1371/journal.pone.0202393. PMID 30106985. Bibcode: 2018PLoSO..1302393P.
31. ↑ "Pocket-Sized Versus Conventional Ultrasound for Detecting Fatty Infiltration of the Liver". Dig Dis Sci. 1 65 (1): 82–85. 2020. doi:10.1007/s10620-019-05752-x. PMID 31376083.
32. ↑ "Non-alcoholic fatty liver disease: An expanded review". World Journal of Hepatology 9 (16): 715–732. June 2017. doi:10.4254/wjh.v9.i16.715. PMID 28652891.
33. ↑ Selvaraj, EA; Mózes, FE; Jayaswal, ANA; Zafarmand, MH; Vali, Y; Lee, JA; Levick, CK; Young, LAJ et al. (October 2021). "Diagnostic accuracy of elastography and magnetic resonance imaging in patients with NAFLD: A systematic review and meta-analysis.". Journal of Hepatology 75 (4): 770–785. doi:10.1016/j.jhep.2021.04.044. PMID 33991635.
34. ↑ Caussy, C; Reeder, SB; Sirlin, CB; Loomba, R (August 2018). "Noninvasive, Quantitative Assessment of Liver Fat by MRI-PDFF as an Endpoint in NASH Trials.". Hepatology (Baltimore, Md.) 68 (2): 763–772. doi:10.1002/hep.29797. PMID 29356032.
35. ↑ Andersson, A; Kelly, M; Imajo, K; Nakajima, A; Fallowfield, JA; Hirschfield, G; Pavlides, M; Sanyal, AJ et al. (November 2022). "Clinical Utility of Magnetic Resonance Imaging Biomarkers for Identifying Nonalcoholic Steatohepatitis Patients at High Risk of Progression: A Multicenter Pooled Data and Meta-Analysis.". Clinical Gastroenterology and Hepatology 20 (11): 2451–2461.e3. doi:10.1016/j.cgh.2021.09.041. PMID 34626833.
36. ↑ Fatty Liver at eMedicine
37. ↑ "Choline deficiency: a cause of hepatic steatosis during parenteral nutrition that can be reversed with intravenous choline supplementation". Hepatology 22 (5): 1399–403. November 1995. doi:10.1002/hep.1840220510. PMID 7590654.
38. ↑ "Lecithin increases plasma free choline and decreases hepatic steatosis in long-term total parenteral nutrition patients". Gastroenterology 102 (4 Pt 1): 1363–70. April 1992. doi:10.1016/0016-5085(92)70034-9. PMID 1551541.
39. ↑ "Choline deficiency causes reversible hepatic abnormalities in patients receiving parenteral nutrition: proof of a human choline requirement: a placebo-controlled trial". Journal of Parenteral and Enteral Nutrition 25 (5): 260–8. 2016. doi:10.1177/0148607101025005260. PMID 11531217.
40. ↑ "The importance of being choline". Journal of the American Dietetic Association 110 (8): 1162–5. August 2010. doi:10.1016/j.jada.2010.05.012. PMID 20656090.
41. ↑ 41.0 41.1 Liu, Jiaye; Ayada, Ibrahim; Zhang, Xiaofang; Wang, Ling; Li, Yang; Wen, Tianfu; Ma, Zhongren; Bruno, Marco J. et al. (February 2021). "Estimating Global Prevalence of Metabolic Dysfunction-Associated Fatty Liver Disease in Overweight or Obese Adults". Clinical Gastroenterology and Hepatology 20 (3): e573–e582. doi:10.1016/j.cgh.2021.02.030. PMID 33618024.
42. ↑ Hamaguchi, Masahide; Kojima, Takao; Takeda, Noriyuki; Nakagawa, Takayuki; Taniguchi, Hiroya; Fujii, Kota; Omatsu, Tatsushi; Nakajima, Tomoaki et al. (15 November 2005). "The Metabolic Syndrome as a Predictor of Nonalcoholic Fatty Liver Disease". Annals of Internal Medicine 143 (10): 722–728. doi:10.7326/0003-4819-143-10-200511150-00009. PMID 16287793.
43. ↑ Sarah Boseley (12 April 2019). "Experts warn of fatty liver disease 'epidemic' in young people". https://www.theguardian.com/society/2019/apr/12/experts-warn-of-fatty-liver-disease-epidemic-in-young-people.
44. ↑ SPINK HEALTH (11 April 2019). "Nonalcoholic fatty liver disease found in large numbers of teenagers and young adults". EurekAlert! (Press release). American Association for the Advancement of Science. Retrieved 4 July 2023.
45. ↑ Cinque, Felice; Cespiati, Annalisa; Lombardi, Rosa; Costantino, Andrea; Maffi, Gabriele; Alletto, Francesca; Colavolpe, Lucia; Francione, Paolo et al. (January 2022). "Interaction between Lifestyle Changes and PNPLA3 Genotype in NAFLD Patients during the COVID-19 Lockdown" (in en). Nutrients 14 (3): 556. doi:10.3390/nu14030556. ISSN 2072-6643. PMID 35276911. 50px Text was copied from this source, which is available under a Creative Commons Attribution 4.0 International License.
46. ↑ Liu, Y.L.; Patman, G.L.; Leathart, J.B.; Piguet, A.C.; Burt, A.D.; Dufour, J.F.; Day, C.P.; Daly, A.K.; Reeves, H.L.; Anstee, Q.M. Carriage of the PNPLA3 rs738409 C >G polymorphism confers an increased risk of non-alcoholic fatty liver disease associated hepatocellular carcinoma. J. Hepatol. 2014, 61, 75–81.
47. ↑ Eslam, M.; Valenti, L.; Romeo, S. Genetics and epigenetics of NAFLD and NASH: Clinical impact. J. Hepatol. 2018, 68, 268–279.
48. ↑ "Role of Growth Hormone Therapy in Metabolic-Dysfunction-Associated Steatotic Liver Disease: A Systematic Review and Meta-Analysis". Indian Journal of Endocrinology and Metabolism 28 (4): 336–342. 2024. doi:10.4103/ijem.ijem_488_23. PMID 39371653.
49. ↑ Lock, Brad (8 August 2017). Hepatic Lipidosis (Fatty Liver Disease) in Reptiles. https://veterinarypartner.vin.com/default.aspx?pid=19239&catId=102919&id=8017925. Retrieved 29 December 2020.
50. ↑ "Fatty Liver Disease in Birds". https://www.animalhouseofchicago.com/news/birds-fatty-liver.
51. ↑ "Fatty Liver Disease in Cats". https://www.petmd.com/cat/conditions/digestive/c_ct_hepatic_lipidosis.
52. ↑ Kalyesubula, Mugagga; Mopuri, Ramgopal; Rosov, Alexander; Alon, Tamir; Edery, Nir; Moallem, Uzi; Dvir, Hay (December 2020). "Hyperglycemia-stimulating diet induces liver steatosis in sheep". Scientific Reports 10 (1): 12189. doi:10.1038/s41598-020-68909-z. PMID 32699301. Bibcode: 2020NatSR..1012189K.
53. ↑ Kalyesubula, Mugagga; Mopuri, Ramgopal; Asiku, Jimmy; Rosov, Alexander; Yosefi, Sara; Edery, Nir; Bocobza, Samuel; Moallem, Uzi et al. (1 March 2021). "High-dose vitamin B1 therapy prevents the development of experimental fatty liver driven by overnutrition". Disease Models & Mechanisms 14 (3): dmm048355. doi:10.1242/dmm.048355. PMID 33608323.

## External links

Classification|

* ICD-10: K70, K76.0
* ICD-9-CM: 571.0, 571.8
* DiseasesDB: 18844

|

External resources|

* eMedicine: med/775 article/170409

* 00474 at CHORUS

* Photo at Atlas of Pathology

* v
* t
* e

Diseases of the digestive system (primarily K20–K93, 530–579)

Upper GI tract|

| Esophagus|

* Esophagitis
* Candidal
* Eosinophilic
* Herpetiform
* Rupture
* Boerhaave syndrome
* Mallory–Weiss syndrome
* UES
* Zenker's diverticulum
* LES
* Barrett's esophagus
* Esophageal motility disorder
* Nutcracker esophagus
* Achalasia
* Diffuse esophageal spasm
* Gastroesophageal reflux disease (GERD)
* Laryngopharyngeal reflux (LPR)
* Esophageal stricture
* Megaesophagus

|

Stomach|

* Gastritis
* Atrophic
* Ménétrier's disease
* Gastroenteritis
* Peptic (gastric) ulcer
* Cushing ulcer
* Dieulafoy's lesion
* Dyspepsia
* Pyloric stenosis
* Achlorhydria
* Gastroparesis
* Gastroptosis
* Portal hypertensive gastropathy
* Gastric antral vascular ectasia
* Gastric dumping syndrome
* Gastric volvulus
* Buried bumper syndrome

Lower GI tract:
Intestinal/
Enteropathy|

| Small intestine
(Duodenum/Jejunum/Ileum)|

* Enteritis
* Duodenitis
* Jejunitis
* Ileitis
* Peptic (duodenal) ulcer
* Curling's ulcer
* Malabsorption: Coeliac
* Tropical sprue
* Blind loop syndrome
* Small bowel bacterial overgrowth syndrome
* Whipple's
* Short bowel syndrome
* Steatorrhea
* Milroy disease
* Bile acid malabsorption

|

Large intestine
(Appendix/Colon)|

* Appendicitis
* Colitis
* Pseudomembranous
* Ulcerative
* Ischemic
* Microscopic
* Collagenous
* Lymphocytic
* Functional colonic disease
* IBS
* Intestinal pseudoobstruction / Ogilvie syndrome
* Megacolon / Toxic megacolon
* Diverticulitis/Diverticulosis

Large and/or small|

* Enterocolitis
* Necrotizing
* Gastroenterocolitis
* IBD
* Crohn's disease
* Vascular: Abdominal angina
* Mesenteric ischemia
* Angiodysplasia
* Bowel obstruction: Ileus
* Intussusception
* Volvulus
* Fecal impaction
* Constipation
* Diarrhea
* Infectious
* Intestinal adhesions

Rectum|

* Proctitis
* Radiation proctitis
* Proctalgia fugax
* Rectal prolapse
* Anismus

Anal canal|

* Anal fissure/Anal fistula
* Anal abscess
* Hemorrhoid
* Anal dysplasia
* Pruritus ani

GI bleeding/BIS|

* Upper
* Hematemesis
* Melena
* Lower
* Hematochezia

Accessory|

| Liver|

* Hepatitis
* Viral hepatitis
* Autoimmune hepatitis
* Alcoholic hepatitis
* Cirrhosis
* PBC
* Fatty liver
* NASH
* Vascular
* Budd–Chiari syndrome
* Hepatic veno-occlusive disease
* Portal hypertension
* Nutmeg liver
* Alcoholic liver disease
* Liver failure
* Hepatic encephalopathy
* Acute liver failure
* Liver abscess
* Pyogenic
* Amoebic
* Hepatorenal syndrome
* Peliosis hepatis
* Metabolic disorders
* Wilson's disease
* Hemochromatosis

|

Gallbladder|

* Cholecystitis
* Gallstones/Cholecystolithiasis
* Cholesterolosis
* Adenomyomatosis
* Postcholecystectomy syndrome
* Porcelain gallbladder

Bile duct/
Other biliary tree|

* Cholangitis
* Primary sclerosing cholangitis
* Secondary sclerosing cholangitis
* Ascending
* Cholestasis/Mirizzi's syndrome
* Biliary fistula
* Haemobilia
* Gallstones/Cholelithiasis

* Common bile duct
* Choledocholithiasis
* Biliary dyskinesia
* Sphincter of Oddi dysfunction

Pancreatic|

* Pancreatitis
* Acute
* Chronic
* Hereditary
* Pancreatic abscess
* Pancreatic pseudocyst
* Exocrine pancreatic insufficiency
* Pancreatic fistula

Abdominopelvic|

| Hernia|

* Diaphragmatic
* Congenital
* Hiatus

* Inguinal
* Indirect
* Direct
* Umbilical
* Femoral
* Obturator
* Spigelian

* Lumbar
* Petit's
* Grynfeltt-Lesshaft

* Undefined location
* Incisional
* Internal hernia
* Richter's

|

Peritoneal|

* Peritonitis
* Spontaneous bacterial peritonitis
* Hemoperitoneum
* Pneumoperitoneum

* v
* t
* e

Alcohol and health

Alcohol use|

| Alcohol-related crimes|

* Drunk drivers
* Alcohol-related traffic crashes in the United States)
* Driving under the influence (DUI)
* Drunk driving in the United States
* Public intoxication
* Rum-running
* Adulterated moonshine/Denatured alcohol
* List of methanol poisoning incidents

|

Alcoholism|

Note: see Template:Psychoactive substance use for diagnoses, and Category:Psychiatric instruments: alcohol abuse for treatment evaluation instruments.

* Alcohol and Native Americans
* Alcoholism in adolescence
* Alcoholism in family systems
* Collaborative Study on the Genetics of Alcoholism
* College student alcoholism
* Disease theory of alcoholism
* High-functioning alcoholic (HFA)
* Seeing pink elephants

Chemistry|

* Beer chemistry
* Congener (Alcohol congener analysis)
* Ethanol (Blood alcohol content, Breathalyzer)
* Fusel alcohol
* Wine chemistry

Effects|

* Effects of alcohol consumption
* short-term
* long-term
* On memory
* Subjective response to alcohol

Interactions|

* Aging
* Brain
* Cancer
* breast cancer
* Cortisol
* Pregnancy
* Sleep
* Tolerance/intolerance
* Weight
* Beverage-specific
* Beer: Potomania
* Red wine: Red wine headache

Social issues|

* Alcohol advertising
* on college campuses
* Sex
* Alcohol myopia
* Alcohol abuse among college students
* Binge drinking
* Epidemiology
* Blackout (alcohol-related amnesia)
* Blackout Wednesday
* Drinking games (list) / pregaming
* Drinking in public
* Drunk dialing
* Drunk walking
* Drunkorexia
* Dry drunk
* French paradox
* Hair of the dog
* Nightcap
* Passive drinking
* Binge drinking devices
* Beer bong
* Yard of ale
* Routes of administration
* Alcohol enema
* Alcohol inhalation
* Sconcing
* Surrogate alcohol
* Related issues
* Balconing
* Suicide

History|

* Dionysian Mysteries
* Dipsomania
* Gin Craze
* List of deaths through alcohol
* Rum ration
* Speakeasy

General|

* Beer day
* Drinking culture
* Apéritif and digestif
* Hangover remedies
* Health effects of wine
* Wine and food matching
* Long-distance race involving alcohol
* List of countries by alcohol consumption per capita
* Alcohol consumption by youth in the United States
* Nip joint

Alcohol control|

| Alcohol law|

* Administrative license suspension (ALS)
* Alcohol packaging warning messages
* Drunk driving law by country
* DWI court
* Field sobriety testing
* Hip flask defence
* Ignition interlock device
* Legal drinking age
* Legal drinking age controversy in the United States
* Underage drinking in America
* List of alcohol laws of the United States

|

Alcohol prohibition|

* List of countries with alcohol prohibition
* Neo-prohibitionism
* Temperance movement

Sobriety|

* Alcohol detoxification
* Alcohol-free zone
* United States open-container laws
* Designated driver
* Alcohol rehabilitation
* Drunk tank
* Managed alcohol program
* Non-alcoholic drink
* List of non-alcoholic cocktails
* List of non-alcoholic mixed drinks
* Non-alcoholic spritzer
* Non-alcoholic malt drinks
* Teetotalism
* Temperance bar
* Twelve-step groups
* Al-Anon/Alateen
* Alcoholics Anonymous (AA):
* Adult Children of Alcoholics (ACA)

Alcohol limitation|

* 0-0-1-3
* Alcohol education
* Alcohol server training
* FRAMES
* Dry January
* Foundation for Advancing Alcohol Responsibility
* Campaigns
* Get Your Sexy Back
* Low-alcohol drinks
* Fermented tea
* Low-alcohol beer
* Low-alcoholic malt drinks
* Small beer
* Measurement
* Alcoholic spirits measure
* Standard drink
* Recommended maximum intake of alcoholic beverages

Addiction medicine|

* Disulfiram-like drugs: disulfiram, calcium carbimide, cyanamide. [[Chemistry:Sulfonic Sulfonic acid]]s: Acamprosate

Religion and alcohol|

* Christian views on alcohol
* alcohol in the Bible
* Islam and alcohol

History|

* Bratt System

Related|

* Index of alcohol-related articles
* Austrian syndrome
* Ban on caffeinated alcoholic beverages
* Brief intervention
* Gateway drug effect
* Mood disorder
* Non-alcoholic fatty liver disease
* Self-medication
* Spins
* Sober companion
* Sober living houses
* Sobering center
* Town drunk

* Category

no:Steatose pl:Alkoholowe stłuszczenie wątroby

0.00

(0 votes)

Original source: https://en.wikipedia.org/wiki/Fatty liver disease. Read more

|

Retrieved from "https://handwiki.org/wiki/index.php?title=Medicine:Fatty_liver_disease&oldid=4238967"
*[v]: View this template
*[t]: Discuss this template
*[e]: Edit this template